Physician profile
Karl E Grunewald
NPI 1285672931
$1,137.43
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $136 · 2022: $52.58 · 2023: $15.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $517.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.08 | 2019-2020 | |
| Janssen Biotech, INC. | $88.01 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $74.51 | 2019-2023 | Sternalock 360 System, Sternalock Blu System |
| Celgene Corporation | $58.97 | 2019-2020 | |
| Becton, Dickinson and Company | $52.58 | 2022 | |
| Smith+Nephew, INC. | $40.13 | 2019 | |
| Puma Biotechnology, INC. | $32.74 | 2019 | |
| Z-Medica, LLC | $32.58 | 2019 | |
| Biomerieux INC | $23.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.68 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.40 | 2019 | |
| Incyte Corporation | $17.53 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $14.94 | 2020 | |
| Tesaro, INC. | $14.45 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.83 | 2020 | |
| Acell, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Grunewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.